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Abstract
Background: Oral corticosteroids (OCSs) are widely prescribed in Otolaryngology-Head & Neck surgery (OtoHNS).
There is evidence in the literature regarding specific dosing regimens. However, it is not known to what extent
these recommendations are being implemented in practice.
Methods: An anonymous online survey was sent to Canadian Society of Otolaryngology-Head and Neck Surgery
members (N = 696). Dosing, frequency and tapering of OCSs were assessed in acute rhino-sinusitis (ARS), chronic
rhino-sinusitis with (CRSwP) and without polyps (CRSsP), sudden sensori-neural hearing loss (SSNHL), and idiopathic
facial nerve/Bell’s palsy (IFN). Participants were asked to complete for conditions treated and results were
compared with current guidelines. Development of prescribing habits and observed complications were also
explored.
Results: 124 surveys (18 %) were completed. In CRSwP (N = 98), the median dose was 50 mg (Range: 10–100 mg)
and the average duration was 8 days (Range: 1–21 days). In CRSsP (N = 29), the median dose was 50 mg (Range:
20-80 mg) and the average duration was 8 days (Range: 1–14 days). In SSNHL (N = 118), the median dose was 60 mg
(Range: 10–120 mg) and the average duration was 10 days (Range: 1–21 days). In IFN (N = 108), the median dose was
50 mg (Range: 10–100 mg) and the average duration was 10 days (Range: 1–21 days). Tapering dosages were used in
treating CRSwP (64 %), CRSsP (62 %), ARS (44 %), SSNHL (60 %) and IFN (53 %). Respondents most frequently perceived
“Mentor/Preceptor Guidance” as a source of their prescribing habits.
Conclusion: There is significant heterogeneity in OCS prescribing habits despite the availability of fairly consistent
evidence in the literature for some of the surveyed conditions. Improvements in standardization should be made
with the aim of enhancing outcomes and reducing complications.
Keywords: Oral corticosteroids, Otolaryngology, Dosing regimen, Evidence-based medicine, Chronic
Rhinosinusitis, Taper, Sudden Sensori-neural Hearing Loss, Facial Nerve Palsy
Background
Oral corticosteroids (OCSs) are commonly used for a
variety of different diseases. In 2013, Overman et al. de-
termined that 1.2 % of the US population over age 20
were prescribed OCSs, translating into over 2.5 million
people [1]. In the field of Otolaryngology-Head & Neck
Surgery (OtoHNS), OCSs are used for several indica-
tions, including chronic rhinosinusitis, sudden sensori-
neural hearing loss, and idiopathic facial nerve, or
Bell’s, palsy.
Due to the significant side effect profile, OCSs are often
reserved as part of maximal medical therapy when other
treatments have not been successful. Complications such
as avascular necrosis of the hip, immunodeficiency, weight
gain, insomnia, and psychosis have been well described in
the literature [2]. While some are idiosyncratic reactions,
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most side effects have been shown to correlate with in-
creasing doses of OCSs [3]. Therefore, the dosing of OCSs
is important to provide maximal benefit while minimizing
potential side effects.
A 2013 UK study by Sylvester et al. qualitatively charac-
terized OCS prescribing habits as part of maximal medical
therapy in chronic rhinosinusitis, with 66 % rarely or
never prescribing OCSs [4]. Of those that did, 42 % uti-
lized a duration of 0-5 days, 29 % for 6–10 days and 29 %
for 11–15 days - suggesting that there is significant het-
erogeneity in prescribing practice in the UK. Kaszuba &
Stewart showed that 36 % of Otolaryngologist-Head &
Neck surgeons used OCSs in chronic rhinosinusitis [5].
This study also concluded that maximal medical manage-
ment was influenced mainly by personal clinical experi-
ences rather than evidence in the literature. Similar
studies have not been conducted in Canada regarding
OCS prescribing habits.
The aim of this study is to characterize OCS prescrib-
ing habits of Canadian Otolaryngologist-Head & Neck
surgeons for chronic rhinosinusitis, acute rhinosinusitis,
sudden sensori-neural hearing loss, and idiopathic facial
nerve (Bell’s) palsy. While the evidence for dosage is het-
erogeneous for some conditions, such as chronic rhino-
sinusitis, a much clearer consensus on dosage exists for
others. This study hopes to provide a glimpse into the
status of evidence-based practice for prescribing OCSs
in Canadian OtoHNS.
Methods
Formal ethics approval was obtained through the Western
University Research Ethics Board (Board number 105523)
prior to beginning the study. An anonymous nationwide
survey was conducted through an online survey program
(QuestionPro.com®) and electronically distributed to all
active members of the Canadian Society of Otolaryngol-
ogy – Head and Neck Surgery’s mailing list (n = 696) be-
tween October and November 2014. A reminder email
was sent approximately 3 months after initial distribution
and participants were incentivized with a gift card draw at
completion of the study. A cover letter accompanied the
survey to outline issues of consent and to disclose the
study’s goal of characterizing prescribing habits of
Canadian Otolaryngologist-Head & Neck surgeons. Re-
spondents were notified that no identifying data would
be included in the study.
Demographic data collected focused on the nature of
respondents’ current practices. Indication, initial dose,
duration, frequency, and use of taper were described for
five common indications of OCSs in OtoHNS. These
were chronic rhinosinusitis with polyposis (CRSwP),
chronic rhinosinusitis without polyposis (CRSsP), acute
rhinosinusitis (ARS), sudden sensori-neural hearing loss
(SSNHL), and idiopathic facial nerve (Bell’s) palsy (IFN).
Respondents were also asked to describe influences that
helped to establish personal dosing regimens as well as
observed complications with the use of OCSs in prac-
tice (Fig. 1).
Results
Out of the 696 survey requests sent to members of the
Canadian Society of Otolaryngology-Head and Neck Sur-
gery, 124 surveys were returned fully completed (18 % re-
sponse rate). The majority of respondents were surgeons
Fig. 1 Components of the online survey. Respondents were asked to answer questions regarding personal demographics, development of prescribing
habits, and specific dosing regimens for CRSwP, CRSsP, ARS, SSNHL, and IFN. Respondents were also asked to describe complications observed
in their practice
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in active practice (87 %). There were slightly more com-
munity practitioners (55 %) than academic practitioners
(40 %). The remaining 5 % had a mixed academic and
community practice. The two most-represented subspe-
cialties were General Otolaryngology (52 %) and Rhinol-
ogy (27 %). These were followed by Pediatrics (23 %),
Head and Neck (20 %), Otology (19 %), Facial Plastic and
Reconstructive Surgery (17 %), Laryngology (12 %) and
other (4 %). The average number of OCSs prescribed by
respondents was 6 prescriptions per month (range: 0–40
prescriptions).
The most common self-described OCS prescribing in-
fluence was a respondent’s mentor or preceptor (78 %),
followed by personal experience (64 %) and clinical guide-
lines (59 %) (see Fig. 2).
Chronic rhinosinusitis
In chronic rhinosinusitis, 79 % of respondents pre-
scribed OCSs for CRSwP and 23 % for CRSsP. The
most common reasons in both cases were “as part of
maximal medical therapy” and “symptomatic exacerba-
tion”. In CRSwP, there were 12 unique doses described
by respondents. The median starting dose was 50 mg
with a range between 10 and 100 mg. The average dur-
ation was 8 days with a range between 1 and 21 days.
In CRSsP, there were 7 unique doses used by respon-
dents. The median dose was 50 mg with a range be-
tween 20 and 80 mg. The average duration was 8 days
with a range between 1 and 14 days. Tapers were used
by approximately two-thirds of those that used cortico-
steroids for both conditions (Table 1, Figs. 3 & 4).
Acute rhinosinusitis
In acute rhinosinusitis, 7 % of respondents reported pre-
scribing OCSs. All nine respondents had unique dosing
regimens. The median dose was 50 mg with a range be-
tween 25 and 60 mg. The average duration was 6 days
with a range between 2 and 10 days. A total of 44 % used
a taper (Table 1, Figs. 3 & 4).
Sudden sensori-neural hearing loss
In SSNHL, an overwhelming majority of respondents used
OCSs (95 %). The most common reason to initiate therapy
was to improve hearing. There were 11 unique dosing reg-
imens described. The median starting dose was 55 mg
with a range between 10 and 100 mg. The most common
starting dose was between 40 and 60 mg of prednisone,
with 98 (80 %) of respondents doing so. The average dur-
ation was 10 days with a range between 1 and 21 days. In
this group of respondents, 60 % utilized a taper (Table 1,
Figs. 3 & 4). Approximately 80 % (98/123) of respondents
used a starting dose between 40 and 60 mg.
Idiopathic facial nerve (Bell’s) palsy
For IFN palsy, 87 % of respondents prescribed OCSs.
There were 9 unique dosing regimens described. The
median dose was 50 mg with a range between 10 and
100 mg. Only 83 (67 %) of respondents used a starting
dose of prednisone between 40 and 60 mg. The average
duration was 9 days with a range between 1 and 21 days.
Of these respondents, 53 % employed a taper (Table 1,
Figs. 3 & 4).
Complications
When asked about complications observed in practice,
30 % of respondents had personally managed patients
with complications from the use of OCSs (Fig. 5). In-
somnia, weight gain and gastrointestinal symptoms were
most commonly described. Other rare complications
were also mentioned including avascular necrosis, ad-
renal suppression, and hypoglycaemia (Fig. 6).
Discussion
This study has characterized the corticosteroid prescrib-
ing habits of Canadian Otolaryngologist-Head & Neck
Fig. 2 Influences for current oral corticosteroid prescribing habits of survey respondents
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surgeons for five common conditions in OtoHNS. The
18 % response rate, which is similar to previous survey
studies of Canadian Otolaryngologist-Head and Neck
surgeons, provides a well-balanced representation of
community and academic practice respondents [6–9].
The results demonstrate the significant variability in pre-
scribing habits, as evidenced by the high number of
unique dosing regimens for each condition. Even greater
variation would likely have been seen with a higher re-
sponse rate, as the findings of this study are in keeping
with the heterogeneity seen in previous surveys for OCS
usage [4]. This is likely to be expected as mentor and
preceptor habits along with personal experience were
most commonly selected as being influences on respon-
dents’ prescribing habits.
For CRSwP, the 2011 Canadian Society of Otolaryngology-
Head and Neck Surgery (CSO-HNS) clinical practice
guidelines suggest a two-week course of OCS to aid in
treatment [10]. It does not elaborate on dosing regi-
mens. A 2013 International Forum of Allergy & Rhinol-
ogy review by Poetker et al. provides a more specific
regimen of 25–60 mg for 7–14 days with Level A evi-
dence from Level 2–4 studies [11]. The Canadian
Family Physician guidelines also provide a dosing regimen
of a two-week course of prednisone with a taper [12]. An
example regimen was given for 30 mg per day for 4 days,
then reduce the dose by 5 mg every 2 days for 10 days.
With these guideline recommendations in mind, it is not
surprising that this study noted 12 unique regimens and a
very wide range of doses (10–100 mg). The guidelines
were unable to commit to a specific regimen, as there
is significant heterogeneity in the literature. For
CRSsP, the same 2011 CSO-HNS guidelines do not
provide any dosing or duration suggestions but pro-
vide a statement supporting the use of a short course
of OCSs in this condition [10]. The 2013 IFAR review
by Poetker et al. provide an optional level C recom-
mendation suggesting 40–60 mg for 10–14 days [11].
This heterogeneity and weakness in the literature for
CRSsP, as well as CRSwP, may be the reason for wide
variety of prescribing habits observed in this study.
Regardless, some of the dosing regimens described by
respondents fall outside of the broad spectrum of rec-
ommendations - either not providing patients with
benefit if too low, or exposing them to unnecessary
potential risk if too high.
Table 1 Dosing regimens responses for CRS, ARS, SSNHL, and IFN/Bell’s Palsy. This table shows the use of OCSs, number of unique
dosing regimens reported, median starting dose, average duration, and taper utilization for CRSwP, CRSsP, ARS, SSNHL, and IFN
Indication Use (% of respondents) Unique dosing regimens Median dose with ranges Duration with ranges Taper (% of respondents)
CRSwP 79 12 50 (10–100) 8 (1–21) 64
CRSsP 23 7 50 (20–80) 8 (1–14) 62
ARS 7 9 50 (25–60) 6 (2–10) 44
SSNHL 95 11 55 (10–120) 10 (1–21) 60
IFN/Bell’s Palsy 87 9 50 (10–100) 9 (1–21) 53
Fig. 3 Initial doses described by respondents for all conditions. Chronic Rhinosinusitis with Polyposis (Blue); Chronic Rhinosinusitis without
Polyposis (Red); Acute Rhinosinusitis (Green); Sudden Sensori-neural Hearing Loss (Purple); Idiopathic Facial Nerve (Bell’s) Palsy (Light Blue)
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The dosing and duration recommendations of cortico-
steroid for SSNHL and IFN palsy, on the other hand, is
more granular. For SSNHL, the American Academy of
Otolaryngology–Head and Neck Surgery clinical guide-
lines recommend the use of OCSs at 60 mg for 10–14
days from level B evidence [13]. In IFN palsy, the
Canadian Medical Association Journal guidelines provide
a strong recommendation for a five-day course of 60 mg
per day followed by a five day taper, reducing the previous
day’s dose by 10 mg per day [14]. It is also suggested that
a total dose of over 450 mg is necessary to obtain optimal
benefit. Only 37 % of respondents prescribed a dose over
this total amount. The evidence supporting these recom-
mendations is stronger than the literature for CRS, and
should provide prescribers with greater guidance as to the
ideal dose and duration of corticosteroid. The results of
this study, in spite of stronger guideline recommenda-
tions, demonstrate that there still is a range in doses and
duration for both conditions with only 80 and 67 % of re-
spondents using the recommended initial dose in SSNHL
and IFN respectively. Prescribing below the guideline
Fig. 4 Durations described by respondents for all conditions. Chronic Rhinosinusitis with Polyposis (Dark Blue); Chronic Rhinosinusitis without
Polyposis (Red); Acute Rhinosinusitis (Green); Sudden Sensori-neural Hearing Loss (Purple); Idiopathic Facial Nerve (Bell’s) Palsy (Light Blue)
Fig 5 Percentage of respondents who have observed a complication
with oral corticosteroids in their practice. Thirty percent of respondents
answered “Yes” (Green) and 70 % answered “No” (Red)
Fig. 6 Complications observed with the use of oral corticosteroids
by respondents
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recommendations could potentially not provide patients
with the intended benefit, while prescribing above could
be exposing patients to unnecessary risk without any fur-
ther additional benefit.
Evidence for corticosteroid use in acute rhinosinusitis
is against routine use and not supported by current
guideline recommendations [10, 15]. In spite of this, 7 %
of respondents in this survey used OCSs in their treat-
ment regimen, likely exposing patients to unnecessary
risk without benefit.
Overall, this study was able to characterize current in-
practice dosing regimens for five common conditions in
which OCSs are used in OtoHNS. Further study needs to
be performed to determine the optimal dose and duration
for OCSs in CRS. However, there is significant heterogen-
eity in OCS prescribing habits irrespective of the strength
of guideline recommendations regarding dose and dur-
ation. Perhaps greater emphasis is needed to encourage
adherence to evidence-based practice to optimize medical
therapy for patients.
Although this study aids in characterizing the dosing
regimens of OCSs used in OtoHNS in Canada, it is
self-reported. Hawthorne effect bias is likely present
when respondents were completing this survey. There-
fore, the results may be an under-estimation of the
variability in the prescribing habits. This would further
strengthen the conclusions made from this study. Add-
itionally, it was difficult to parse out the reason for re-
spondents to select “Yes” or “No” when replying to
questions regarding the use of OCSs in each of the con-
ditions mentioned in the survey. Some may have inter-
preted it as a question inquiring about the use of OCSs
in their practice while others may have understood it as
a question of whether they believed in prescribing
OCSs for each specific condition. This would have po-
tentially skewed the results of this question for each of
the conditions. Further clarification of the question
would have been optimal along with a third option of
“Do not prescribe in my practice”.
Conclusion
OCSs are widely used in OtoHNS. This study provides a
glimpse into the in-practice prescription habits of
Canadian Otolaryngologist-Head & Neck surgeons for
chronic rhinosinusitis with and without polyps, acute
rhinosinusitis, sudden sensori-neural hearing loss, and
idiopathic facial nerve palsy. As expected, there is a wide
range of dosing regimens currently being used – some
being within the recommended guidelines and others
that are not. Further research to standardize prescribing
habits in order to optimize patient outcomes and
minimize potential risk from unnecessarily high doses of
corticosteroid would be beneficial.
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